Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.
Nishio M, et al. Among authors: kudo k.
Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.
Invest New Drugs. 2015.
PMID: 25777467
Clinical Trial.